Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on July 31, 2025, declared Interim Dividend of Rs. 6 per equity share.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Smallcap 250 and 1.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Dr. Lal PathLabs, at its meeting on July 31, 2025, approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Consolidated revenue from operations rose to roughly Rs. 6,407 million from Rs. 6,043 million in the year-ago quarter, while consolidated profit for the period fell to about Rs. 1,293 million from Rs. 1,484 million (restated). Standalone profit also declined to around Rs. 1,145 million from Rs. 1,484 million, with standalone EPS at Rs. 13.76 vs Rs. 17.78. The Board declared an interim dividend of Rs. 6 per equity share (60% on face value of Rs. 10) for FY26, with August 6, 2025 as the record date. Prior period numbers have been restated to reflect the voluntary liquidation of subsidiary Suburban Diagnostics (India) Pvt. Ltd, which was completed in March 2025 and resulted in a deferred tax credit of Rs. 408 million.
Shareholders on the record date will receive Rs. 6 per share as interim dividend, signaling steady cash generation. However, the YoY decline in both standalone and consolidated profits and the restatement of prior figures may draw investor attention, though the underlying diagnostics business continues to show revenue growth.